business info

  • Musculoskeletal
  • Gastrointestinal (GI)
  • Cardiovascular (CV)
  • Urology
  • Antibiotics
  • Blood Preparetions
  • Vaccines
  • Parenteral Nutritions
  • Other Rx
HOME › Product info › Other Rx

Other Rx

futhan lnj futhan lnj
  • Futhan has potent inhibitory activity on wide spectrum of proteases, i.e. coagulation-fibrinolysis system, kallikrein-kinin system, complement system and pancreatic enzymes.
  • Futhan effectively inhibits aggravation of acute pancreatitis as well as improves acute symptoms of pancreatitis.
  • Futhan also shows excellent anticoagulating effect to prevent clotting during ECC(extracorporeal circulation) and thrombosis occurred in DIC(disseminated intravascular coagulation).
  • Futhan also shows excellent anticoagulating effect to prevent clotting during ECC(extracorporeal circulation) and thrombosis occurred in DIC(disseminated intravascular coagulation).
  • descriptin
    Futhan inj. : 1 vial contains 10mg of nafamostat mesilate
    Futhan50 inj. : 1 vial contains 50mg of nafamostat mesilate
  • indication &usage
    1. 1. For improvement of acute symptoms of pancreatitis (acute pancreatitis, acute exacerbation of chronic pancreatitis, acute postoperative pancreatitis, ERCP-induced acute pancreatitis, traumatic pancreatitis)
    2. 2. Disseminated Intravascular Coagulation (DIC)
    3. 3. To prevent coagulation of blood during extracorporeal blood circulation (ex. hemodialysis, plasmapheresis) in patients with bleeding complications or bleeding tendency.
  • dosage &administration
    1. 1. For improvement of acute symptoms of pancreatitis Usually, 10mg of nafamostat mesilate dissolved in 500ml of 5% glucose solution is drip-infused intravenously over about 2 hours, once or twice a day. The dosage can be individually adjusted according to the severity of symptoms.

    2. 2. Disseminated Intravascular Coagulation (DIC) Usually, one-day dose dissolved in 1000ml of 5% glucose solution is drip-infused intravenously over 24 hours at the rate of 0.06~0.20mg/kg/hr as nafamostat mesilate.

    3. 3. To prevent coagulation of blood during extracorporeal blood circulation For priming, wash and fill the blood route with 500ml of saline containing 20mg of nafamostat mesilate. After beginning of extracorporeal circulation, inject continuously 20~50mg/hr of nafamostat mesilate dissolved in 5% glucose solution into anticoagulant injection line. The dosage should be appropriately adjusted according to the patient’s symptoms. The average dosage from clinical studies is 35mg/hr as nafamosat mesilate.
    4. characteristics
      In the area of ECC
      1. ① Futhan is the safest anticoagulant for patients at high bleeding risk. Due to it short half life, the activity of Futhan is almost limited to extracorporeal circuit not to affect the coagulation ability of the intracorporeal blood.
      2. ② Dosaging & monitoring is convenient compared with conventional methods for high bleeding risk patients.
      3. ③ Excellent anticoagulating activity of Futhan guarantees high efficiency of the treatment.

list